Children with meningitis due to Streptococcus pneumoniae isolates that are relatively or fully resistant to penicillin and have decreased susceptibility to broad-spectrum cephalosporins (MIC, .2.0 ,ug/ml) who have failed treatment with broad-spectrum cephalosporins have been reported. The National Committee for Clinical Laboratory Standards has newly revised guidelines indicating that S. pneumoniae isolates associated with meningitis for which the MICs are .0.5 ,ug/ml should be considered resistant to broad-spectrum cephalosporins. This recommendation is not clearly based on data related to clinical outcome and may be too conservative.
The first case of penicillin-resistant Streptococcus pneumoniae meningitis in the United States was reported by Naraqi et al. (17) in 1974. Additional cases of meningitis caused by S. pneumoniae relatively resistant (MIC, 0.1 to 1.0 ,ug/ml) or fully resistant (MIC, >2.0 jig/ml) to penicillin have been reported over the last 15 to 18 years (1, 6, 10, 11, 14, 20, 21, 23, 26, 27) . The broad-spectrum cephalosporins ceftriaxone and cefotaxime are the most commonly recommended antibiotics for treatment of meningitis due to penicillin-resistant S. pneumoniae, although the optimal antibiotic therapy for meningitis due to penicillin-resistant S. pneumoniae has not been established (11, 13, 15, 16, 23, 27) . However, over the last 4 years, children with meningitis due to S. pneumoniae isolates which have decreased susceptibility to broad-spectrum cephalosporins (MICs, .2.0 ,ug/ml) and who have been unsuccessfully treated with broad-spectrum cephalosporins have been reported (2-5, 9, 12, 21) .
The National Committee for Clinical Laboratory Standards has established new guidelines stating that S. pneumoniae isolates associated with meningitis for which the MICs are -0.5 Lg/ml should be considered resistant to broad-spectrum cephalosporins. However, this recommendation is not clearly based on data related to clinical outcome.
We present our experience with five children who had S. pneumoniae meningitis due to isolates that were relatively or fully resistant to penicillin (MIC range, 0.125 to 4.0 ,ug/ml) and had cefotaxime or ceftriaxone MICs ranging from 0.50 to 2.0 ,ug/ml. All were treated with cefotaxime, and their clinical courses and outcomes were compared with those of five patients with S. pneumoniae meningitis due to strains that were relatively or fully resistant to penicillin and were inhibited by cefotaxime at concentrations of .0.25 ,ug/ml and with those of 25 patients with S. pneumoniae meningitis due to penicillinsusceptible isolates identified during the same period.
MATERUILS AND METHODS
All clinical isolates of S. pneumoniae recovered from 1 January 1989 to 30 June 1993 in the microbiology laboratories of Texas Children's Hospital, Houston, and Arkansas Children's Hospital, Little Rock, were routinely screened for penicillin susceptibility with a 1-Rig oxacillin disk by the KirbyBauer disk diffusion method. Strains which showed a zone of inhibition less than 20 mm in diameter were considered possibly resistant to penicillin and underwent additional testing for confirmation (18 Patients with S. pneumoniae isolates having cefotaxime MICs of .0.50 ,Ig/ml. Isolates from five patients had penicillin MICs ranging from 1.0 to 4.0 ,g/ml ( Table 1 ). The mean age of the patients was 16 months, and 60% of these children were females. Three of the patients were Caucasian, one was Afro-American, one was Hispanic, and none had an underlying condition.
The initial CSF parameters for these patients showed a mean leukocyte (WBC) count of 1,579/mm3. The mean protein and glucose concentrations were 219 and 37 mg/dl, respectively. All of the patients had Gram stains positive for grampositive cocci and cultures positive for S. pneumoniae. All of the patients were treated with cefotaxime for a total dose of 200 to 225 mg/kg/day divided into doses administered every 6 to 8 h for courses ranging from 10 to 18 days. One patient each also received ampicillin for 2 days and nafcillin for 4 days. Two patients also received a 4-day course of dexamethasone. Three of the patients had positive blood cultures at the time of admission; all had repeat blood cultures which were negative within 48 h of the initial positive culture. Three of the patients had repeat lumbar punctures; two were performed within 72 h of the initial positive CSF culture, and one was performed after 14 (24) used a rabbit meningitis model to determine which method of ceftriaxone MIC determination best correlates with the in vivo response to ceftriaxone therapy by using a patient's isolate. The isolate studied had a ceftriaxone MIC of <0.5 ,ug/ml as determined by a commercial MIC panel but an MIC of 4.0 ,ug/ml when evaluated by the conventional microtiter broth dilution technique. The investigators demonstrated that when this isolate was used to induce meningitis, there was little change in bacterial concentrations in CSF, even when higher doses of ceftriaxone were used, but when a pneumococcal strain with a ceftriaxone MIC of 0.5 ,ug/ml was used to induce meningitis, the same dose of ceftriaxone reduced bacterial concentrations in CSF significantly. On the basis of these experimental data, the investigators propose that broad-spectrum cephalosporins alone may not be sufficient therapy for any S. pneumoniae CSF strain with a cefotaxime or ceftriaxone MIC of . (8) performed Kirby-Bauer disk susceptibility tests with five standard cephalosporin disks (cephalothin, ceftriaxone, ceftizoxime, cefotaxime, and cefuroxime, all at 30 jig/ml) on 23 penicillin-resistant (MIC range, 0.1 to >2.0 ,ug/ml) pneumococcal strains, including 5 strains for which the ceftriaxone MICs were -2.0 jLg/ml. They found that the cefuroxime disk clearly distinguished strains for which the ceftriaxone MICs were .2.0 ,ug/ml from those for which the MICs were <2.0 ,ug/ml and that the ceftizoxime disk provided the clearest means of distinguishing strains for which the MICs were -1.0 ,ug/ml from more susceptible strains. Which screening test should be employed on a routine basis is not certain.
On the basis of our limited number of patients, the clinical outcome of children who had meningitis due to penicillinresistant S. pneumoniae for which the cefotaxime or ceftriaxone MICs are 0.50 to 1.0 ,ug/ml and who were treated with a parenterally administered broad-spectrum cephalosporin was comparable at the time of discharge to that of patients with penicillin-resistant or -susceptible isolates for which the cefotaxime or ceftriaxone MICs were .0.25 jig/ml. There were no meningitis relapses in any of these patients. Our patients provide a clinical basis upon which cefotaxime or ceftriaxone MIC breakpoints for S. pneumoniae can be considered. On the basis of this experience, a broad-spectrum cephalosporin should be initiated and continued in the treatment of a patient with penicillin-resistant S. pneumoniae meningitis in areas where high-level cephalosporin resistance (MIC, -2.0 ,ug/ml) has not been reported. In a child with meningitis found to have an S. pneumoniae isolate with a cefotaxime or ceftriaxone MIC of 0.5 to 1.0 ,ug/ml, cefotaxime or ceftriaxone can be continued if the patient is improving clinically (more alert and active, fever decreasing, etc.) and repeat CSF parameters suggest successful therapy (especially negative Gram stain and culture). If the patient fails to improve or if the CSF culture remains positive, alternative therapy is required. Vancomycin and chloramphenicol are the most commonly recommended agents in this circumstance.
